메디포스트

078160KOSDAQ기초 의약물질 제조업

44.1 / 100

Reference Date: 2026-06-10

Financial Score12.5 / 40

News Sentiment19.6 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Plunged 62.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medipost operates three main business segments: umbilical cord blood banking, stem cell therapeutics (Cartistem), and health functional foods. In 2024, the company achieved a record sales revenue of 70.7 billion won, driven by strong performance in its cord blood banking division, which holds the top market share domestically, and its stem cell therapeutics division expanding global clinical trials.

Number of Employees

684people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

1.55Industry Average 1.744.0Point

In line with industry avg

ROE

-34.23Industry Average -6.033.5Point

5.7x industry avg (excellent)

Debt Ratio

33.95Industry Average 6.620.0Point

5.1x industry avg (risky)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼66.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.2% (declining, 3yr)

Detailed News Sentiment

10 totalPositive 8Neutral 1Negative 1Average Sentiment Score 78.5

Positive
메디포스트 “美 FDA, 카티스템 단일 ‘임상 3상’ 승인”
메디포스트의 카티스템이 FDA로부터 임상 3상 진행 방식 변경 승인을 받아 신약 개발 효율성 향상 기대.
Positive
메디포스트, 종속회사에 227억원 추가 출자 결정
메디포스트가 종속회사에 대한 추가 투자로 자금 지원 강화, 기업 성장 기대감 상승.
Positive
FDA 문턱 낮춘 카티스템…美 임상 부담 줄었다
메디포스트의 카티스템이 FDA 임상 절차 간소화로 인해 개발 기간 단축과 비용 절감이 기대되어 긍정적 영향을 받을 것으로 보인다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 9,850Won52-week high 28,00052-week low 9,850

1-month return0.0Point

1m -62.69% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral타법인주식및출자증권취득결정2026-06-04
Neutral분기보고서 (2026.03)2026-05-15